Jose Baselga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jose Baselga has a total of 882 co-authors. Here are the top co-authors by number of shared publications:
J. Cortes
13 shared publicationsJ. Tabernero
13 shared publicationsC. Saura
10 shared publicationsF. Rojo
8 shared publicationsM. Vidal
8 shared publicationsS. Di Cosimo
8 shared publications
Latest Publications
- 1 December 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 69, S122-S123
Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors
- 1 December 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 69, S122-S123
Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi84
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi84
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown.
- 1 July 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 61, S123
PI3K blockade reverses primary resistance and adaptation to eribulin in PI3K-pathway activated breast cancer tumors
- 1 July 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 61, S123
PI3K blockade reverses primary resistance and adaptation to eribulin in PI3K-pathway activated breast cancer tumors
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S586
2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S586
2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv150
Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)
Aim: BYL719 is a selective oral inhibitor of the Class l PI3K α-isoform. PI3Kα is encoded by PIK3CA, a frequently altered gene in human cancers. This was a Ph I, dose-escalation and -expansion, first-in-human study of BYL719 in pts with PIK3CA-altered aST, or PIK3CA-altered or wild-type (wt) ER+ breast cancer (BC) (NCT01219699). Methods: Adult pts with advanced PIK3CA-altered (mutation or amplification) aST received oral BYL719 QD or BID (28-day cycles). Pts with PIK3CA wt ER+ BC were also enrolled into the dose expansion. A Bayesian logistic regression model with overdose control guided dose escalation. Primary objective was to determine MTD and/or RP2D of single-agent BYL719. Safety (CTCAE v4.0), tolerability, PK, preliminary efficacy (RECIST) were also assessed. Results: As of Mar 10, 2014, 132 pts received BYL719 QD (30–450 mg) or BID (120, 150, 200 mg). Median exposure was 11.9 (0.4–98) wks. DLTs were reported in: 4 pts (hyperglycemia x2, nausea x2) at 450 mg QD, 4 pts (hyperglycemia x4) at 200 mg BID, and 1 pt (hyperglycemia and hypophosphatemia) at 150 mg BID. BYL719 QD MTD is 400 mg (and was used for dose expansion); here, BYL719 BID MTD is declared as 150 mg. Most common (≥20%) suspected study drug-related all-Grade AEs at the MTDs were: BYL719 150 mg BID (n = 15) – hyperglycemia, nausea (both 53%), diarrhea, decreased appetite, fatigue, stomatitis (all 33%); and BYL719 400 mg QD (n = 63 including dose expansion) – hyperglycemia (51%), nausea (48%), diarrhea (41%), decreased appetite (38%), fatigue (32%), vomiting (30%), rash (20%). Overall, 15 of 131 evaluable pts had partial responses (PRs; incl. 2 [out of 24 pts] with PIK3CA-altered ER+ BC); 7 PRs were confirmed: 2 at 270 mg QD, 1 at 350 mg QD, 2 at 400 mg QD, 2 at 150 mg BID. Disease control rates (CR, PR, or SD) at MTDs were: BYL719 400 mg QD – 53%; and BYL719 150 mg BID – 67%. Median PFS at ≥270 mg in ER+ HER2– BC (n = 21) was 166 days. In pts with PIK3CA wt ER+ BC (n = 5) duration of exposure range was 7–61 days; no PRs were observed in wt pts. Conclusions: BYL719 is the first α isoform-specific PI3K inhibitor to show single-agent responses in tumors with activating mutations. The safety profile was favorable with mostly on-target effects (i.e. hyperglycemia). Data comparing PIK3CA-altered and wt ER + /HER2– BC pts will be presented. Disclosure: D. Juric: I have participated on scientific advisory board meetings for Novartis. No other conflicts of interest; M. Schuler: Ad Board/Consultant (Compensated): AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer Research grants: Boehringer Ingelheim, Novartis Honoraries for CME lectures: Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly, Novartis, Pfizer; J. Berlin: Vanderbilt Cancer Center receives research support from Novartis for this trial. I personally do not receive funding; R. Seggewiß-Bernhardt: I have been on the Novartis' advisory board meeting \"From bench to bed - Anforderungen an Translationale Konzepte\", 5 & 6 March 2014 in Basel, Switzerland; J. Rodon: Attendance as consultant to a Novartis Advisory Board that was compensated; J. Tabernero: Consultant or advisory role: Amgen, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Roche, Sanofi, Celgene, Chugai and Taiho; F. Janku: I have research funding from Novartis; H.S. Rugo: I received Research Support on behalf of my university to conduct trials from Novartis. I have received travel support from Novartis; D. Bootle: I am an employee of Novartis, C. Quadt: I am employee of Novartis Oncology and own Novartis shares; C. Coughlin: I am an employee of Novartis; D. Demanse: I have an employment to disclose: Statistician at Novartis; L. Blumenstein: I am an employee of Novartis. All other authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv150
Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)
Aim: BYL719 is a selective oral inhibitor of the Class l PI3K α-isoform. PI3Kα is encoded by PIK3CA, a frequently altered gene in human cancers. This was a Ph I, dose-escalation and -expansion, first-in-human study of BYL719 in pts with PIK3CA-altered aST, or PIK3CA-altered or wild-type (wt) ER+ breast cancer (BC) (NCT01219699). Methods: Adult pts with advanced PIK3CA-altered (mutation or amplification) aST received oral BYL719 QD or BID (28-day cycles). Pts with PIK3CA wt ER+ BC were also enrolled into the dose expansion. A Bayesian logistic regression model with overdose control guided dose escalation. Primary objective was to determine MTD and/or RP2D of single-agent BYL719. Safety (CTCAE v4.0), tolerability, PK, preliminary efficacy (RECIST) were also assessed. Results: As of Mar 10, 2014, 132 pts received BYL719 QD (30–450 mg) or BID (120, 150, 200 mg). Median exposure was 11.9 (0.4–98) wks. DLTs were reported in: 4 pts (hyperglycemia x2, nausea x2) at 450 mg QD, 4 pts (hyperglycemia x4) at 200 mg BID, and 1 pt (hyperglycemia and hypophosphatemia) at 150 mg BID. BYL719 QD MTD is 400 mg (and was used for dose expansion); here, BYL719 BID MTD is declared as 150 mg. Most common (≥20%) suspected study drug-related all-Grade AEs at the MTDs were: BYL719 150 mg BID (n = 15) – hyperglycemia, nausea (both 53%), diarrhea, decreased appetite, fatigue, stomatitis (all 33%); and BYL719 400 mg QD (n = 63 including dose expansion) – hyperglycemia (51%), nausea (48%), diarrhea (41%), decreased appetite (38%), fatigue (32%), vomiting (30%), rash (20%). Overall, 15 of 131 evaluable pts had partial responses (PRs; incl. 2 [out of 24 pts] with PIK3CA-altered ER+ BC); 7 PRs were confirmed: 2 at 270 mg QD, 1 at 350 mg QD, 2 at 400 mg QD, 2 at 150 mg BID. Disease control rates (CR, PR, or SD) at MTDs were: BYL719 400 mg QD – 53%; and BYL719 150 mg BID – 67%. Median PFS at ≥270 mg in ER+ HER2– BC (n = 21) was 166 days. In pts with PIK3CA wt ER+ BC (n = 5) duration of exposure range was 7–61 days; no PRs were observed in wt pts. Conclusions: BYL719 is the first α isoform-specific PI3K inhibitor to show single-agent responses in tumors with activating mutations. The safety profile was favorable with mostly on-target effects (i.e. hyperglycemia). Data comparing PIK3CA-altered and wt ER + /HER2– BC pts will be presented. Disclosure: D. Juric: I have participated on scientific advisory board meetings for Novartis. No other conflicts of interest; M. Schuler: Ad Board/Consultant (Compensated): AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer Research grants: Boehringer Ingelheim, Novartis Honoraries for CME lectures: Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly, Novartis, Pfizer; J. Berlin: Vanderbilt Cancer Center receives research support from Novartis for this trial. I personally do not receive funding; R. Seggewiß-Bernhardt: I have been on the Novartis' advisory board meeting \"From bench to bed - Anforderungen an Translationale Konzepte\", 5 & 6 March 2014 in Basel, Switzerland; J. Rodon: Attendance as consultant to a Novartis Advisory Board that was compensated; J. Tabernero: Consultant or advisory role: Amgen, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Roche, Sanofi, Celgene, Chugai and Taiho; F. Janku: I have research funding from Novartis; H.S. Rugo: I received Research Support on behalf of my university to conduct trials from Novartis. I have received travel support from Novartis; D. Bootle: I am an employee of Novartis, C. Quadt: I am employee of Novartis Oncology and own Novartis shares; C. Coughlin: I am an employee of Novartis; D. Demanse: I have an employment to disclose: Statistician at Novartis; L. Blumenstein: I am an employee of Novartis. All other authors have declared no conflicts of interest.
- Open Access
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix73-ix94
Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project
The prevalence of ALK gene rearrangement (ALK+) in European patients with non-small cell lung cancer (NSCLC) is unknown. The Lungscape project provides a platform to evaluate its expression and clinical significance in a large cohort of patients with resected NSCLC from 13 European sites in 11 countries.
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix73-ix94
Open AccessPrevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project
The prevalence of ALK gene rearrangement (ALK+) in European patients with non-small cell lung cancer (NSCLC) is unknown. The Lungscape project provides a platform to evaluate its expression and clinical significance in a large cohort of patients with resected NSCLC from 13 European sites in 11 countries.
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S349
5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S349
5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e21130
Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status.
E21130 Background: In breast cancer (BC), PI3K pathway activation is frequently identified and is a potential target for therapies currently in development. Nowadays, the role of PIK3CA mutation as a prognostic marker is controversial. The aim of this study is to determine the prognostic implications of PI3K pathway in MBC and to correlate it with BC subtypes. Methods: We analyzed 148 MBC pts. DNA was extracted from paraffin-embedded tumor tissue with EZ1 DNA Tissue Kit and was analyzed with DxS PI3K Mutation Test Kit or Sequenom MALDI-TOF MassARRAY technology. PTEN status was determined by immunohistochemistry and PTEN loss was defined as H-score ≤50. All pts signed informed consent. SPSS v.15 software was used for statistical analysis. Results: PIK3CA status was tested in 119 pts and mutations were found in 44 (37%): 26 (59%) in exon 20 [H1047R] and 18 in exon 9 [11 E545K, 5 Q546K and 2 E542K]. PIK3CA mutations were present in 35% of hormonal receptor positive BC group (HR+), 21% of HER2 positive (HER2+) and 25% of triple negative BC (TNBC). In HR+, the frequency of mutations in exon 9 was higher (52%) than in HER2+ (14%) and TNBC (25%) (p=0.057). PTEN H-score was determined in 142 pts; loss of function was present in 40 pts (28%): 23 (57%) of HR+ tumors, 10 (25%) of TNBC and 7 (18%) of HER2 +. There is no significant difference in PTEN expression between BC subtypes. PIK3CA mutation and PTEN loss of function were not mutually exclusive as 9 pts had both alterations assessed. In pts with PIK3CA mutation and/or PTEN loss OS was shorter compared to wild-type cases (p=0.009). Among those with a PI3K pathway alteration, TNBC was associated with shorter OS, but not HR+ and/or HER2+ (p=0.015). No differences were found in disease free survival among different BC subtypes. Overall, 17 pts were enrolled in a PI3K-pathway inhibitor phase 1 clinical trial. Conclusions: In our BC population, the prevalence of the different PIK3CA mutations and PTEN loss rates correlates with previous published data. A higher frequency of exon 9 mutations was found in HR+ compared with HER2+ and TNBC. In our database, PI3K pathway alteration is associated with lower OS, especially among TNBC pts.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e21130
Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status.
E21130 Background: In breast cancer (BC), PI3K pathway activation is frequently identified and is a potential target for therapies currently in development. Nowadays, the role of PIK3CA mutation as a prognostic marker is controversial. The aim of this study is to determine the prognostic implications of PI3K pathway in MBC and to correlate it with BC subtypes. Methods: We analyzed 148 MBC pts. DNA was extracted from paraffin-embedded tumor tissue with EZ1 DNA Tissue Kit and was analyzed with DxS PI3K Mutation Test Kit or Sequenom MALDI-TOF MassARRAY technology. PTEN status was determined by immunohistochemistry and PTEN loss was defined as H-score ≤50. All pts signed informed consent. SPSS v.15 software was used for statistical analysis. Results: PIK3CA status was tested in 119 pts and mutations were found in 44 (37%): 26 (59%) in exon 20 [H1047R] and 18 in exon 9 [11 E545K, 5 Q546K and 2 E542K]. PIK3CA mutations were present in 35% of hormonal receptor positive BC group (HR+), 21% of HER2 positive (HER2+) and 25% of triple negative BC (TNBC). In HR+, the frequency of mutations in exon 9 was higher (52%) than in HER2+ (14%) and TNBC (25%) (p=0.057). PTEN H-score was determined in 142 pts; loss of function was present in 40 pts (28%): 23 (57%) of HR+ tumors, 10 (25%) of TNBC and 7 (18%) of HER2 +. There is no significant difference in PTEN expression between BC subtypes. PIK3CA mutation and PTEN loss of function were not mutually exclusive as 9 pts had both alterations assessed. In pts with PIK3CA mutation and/or PTEN loss OS was shorter compared to wild-type cases (p=0.009). Among those with a PI3K pathway alteration, TNBC was associated with shorter OS, but not HR+ and/or HER2+ (p=0.015). No differences were found in disease free survival among different BC subtypes. Overall, 17 pts were enrolled in a PI3K-pathway inhibitor phase 1 clinical trial. Conclusions: In our BC population, the prevalence of the different PIK3CA mutations and PTEN loss rates correlates with previous published data. A higher frequency of exon 9 mutations was found in HR+ compared with HER2+ and TNBC. In our database, PI3K pathway alteration is associated with lower OS, especially among TNBC pts.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 554
PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
554 Background: Gene expression profiling can be used to predict the likelihood of achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (CT) in patients with primary breast cancer. We report a retrospective exploratory analysis to evaluate the utility of the PAM50 subtype assay in predicting pCR in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial, which recruited 334 patients. Methods: Formalin-fixed paraffin-embedded core biopsies were collected from 156 patients randomized to receive doxorubicin/paclitaxel (AT) followed by CMF (Group 1; HER2-positive/negative), or the same regimen with trastuzumab (H) (AT+H→CMF+H; Group 2; HER2-positive). Total RNA was amplified, labeled, and hybridized onto Affymetrix 2.0 Plus microarrays. The PAM50 microarray-based assay was applied to 43 genes. The PAM50 Risk Of Relapse score based on subtype and Proliferation (RORP) was evaluated as a continuous variable and as low/medium/high-risk groups using previously reported cutoffs. pCR was defined by the absence of residual invasive tumor in the breast and axillary lymph nodes. Univariate logistic regression was used to evaluate the association of each signature with pCR. Results: Overall pCR rates were 21.5% (20/93) and 44.4% (28/63) in Groups 1 and 2, respectively (p<0.005). In Group 1, non-LumA tumors showed higher pCR rates than LumA tumors (27% vs. 0%, p<0.005). Low, medium and high RORP groups showed 0%, 19% and 37% pCR rates (p=0.02). In Group 2, all subtypes were identified and HER2-enriched tumors showed a non-significant increase in pCR rates compared to non-HER2-enriched tumors (53% vs. 34%). Low, medium and high RORP groups showed 17%, 36% and 75% pCR rates (p=0.01). In Group 2 the odds ratio for achieving a pCR in the high-risk RORP group was 15.0 compared to the low-risk group (p=0.029). Conclusions: HER2-positive tumors predicted to have a high risk of relapse by the PAM50 assay benefited substantially from H-based CT. Similar findings are observed in HER2-positive/negative tumors treated with CT only. The role of PAM50 and/or other genomics assays in predicting pCR and survival during treatment with anti-HER2 agents warrants further investigation.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 554
PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
554 Background: Gene expression profiling can be used to predict the likelihood of achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (CT) in patients with primary breast cancer. We report a retrospective exploratory analysis to evaluate the utility of the PAM50 subtype assay in predicting pCR in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial, which recruited 334 patients. Methods: Formalin-fixed paraffin-embedded core biopsies were collected from 156 patients randomized to receive doxorubicin/paclitaxel (AT) followed by CMF (Group 1; HER2-positive/negative), or the same regimen with trastuzumab (H) (AT+H→CMF+H; Group 2; HER2-positive). Total RNA was amplified, labeled, and hybridized onto Affymetrix 2.0 Plus microarrays. The PAM50 microarray-based assay was applied to 43 genes. The PAM50 Risk Of Relapse score based on subtype and Proliferation (RORP) was evaluated as a continuous variable and as low/medium/high-risk groups using previously reported cutoffs. pCR was defined by the absence of residual invasive tumor in the breast and axillary lymph nodes. Univariate logistic regression was used to evaluate the association of each signature with pCR. Results: Overall pCR rates were 21.5% (20/93) and 44.4% (28/63) in Groups 1 and 2, respectively (p<0.005). In Group 1, non-LumA tumors showed higher pCR rates than LumA tumors (27% vs. 0%, p<0.005). Low, medium and high RORP groups showed 0%, 19% and 37% pCR rates (p=0.02). In Group 2, all subtypes were identified and HER2-enriched tumors showed a non-significant increase in pCR rates compared to non-HER2-enriched tumors (53% vs. 34%). Low, medium and high RORP groups showed 17%, 36% and 75% pCR rates (p=0.01). In Group 2 the odds ratio for achieving a pCR in the high-risk RORP group was 15.0 compared to the low-risk group (p=0.029). Conclusions: HER2-positive tumors predicted to have a high risk of relapse by the PAM50 assay benefited substantially from H-based CT. Similar findings are observed in HER2-positive/negative tumors treated with CT only. The role of PAM50 and/or other genomics assays in predicting pCR and survival during treatment with anti-HER2 agents warrants further investigation.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 3105
Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).
3105 Background: AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. Methods: This open-label (3+3 design) study (NCT00900627) evaluated the MTD, safety, tolerability and PK of AZD8931 (40–160 mg bid) combined with P (90 mg/m2 on days 1, 8 and 15 of a 28-day cycle). DLTs were evaluated during Cycle 1. AZD8931 dosing started at 160 mg bid (based on monotherapy study results; NCT00637039). Results: 20 pts with advanced refractory tumors (16 breast) received AZD8931. Median exposure to AZD8931 was 52 days and to P was 3 cycles. In the 160 mg bid cohort, DLTs occurred in 2/6 pts (Gr 3 rash; Gr 3 keratitis and Gr 3 photophobia), leading to lower dose cohorts. DLTs occurred in 1/2 pts at 120 mg bid (Gr 3 diarrhea) and 2/6 pts at 80 mg bid (Gr 3 rash; Gr 3 esophagitis). AZD8931 40 mg bid was the protocol-defined MTD. At AZD8931 40 mg bid + P, skin rash (n=6) and diarrhea (n=5) were the most common dermatology and GI-related AEs; the majority were of short duration, and responded to appropriate management and/or temporary AZD8931 interruption. At 40 mg bid, AZD8931 steady-state concentrations exceeded preclinical IC50s for target receptors. Combination treatment did not alter exposure of AZD8931 or P (preliminary data). Conclusions: AZD8931 40 mg bid was generally well tolerated, considered suitable for chronic administration, and is progressing into phase II. Experience in this study has highlighted the importance of early rash management and robust guidelines have been adopted. The difference in AZD8931 MTD between this and the monotherapy study most probably reflects differences in clinical interpretation of DLT criteria as they pertained to non life-threatening and subjective events such as rash, more long-term exposure in the present study, and the possible augmentation of rash when EGFR inhibition is combined with P.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 3105
Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P).
3105 Background: AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. Methods: This open-label (3+3 design) study (NCT00900627) evaluated the MTD, safety, tolerability and PK of AZD8931 (40–160 mg bid) combined with P (90 mg/m2 on days 1, 8 and 15 of a 28-day cycle). DLTs were evaluated during Cycle 1. AZD8931 dosing started at 160 mg bid (based on monotherapy study results; NCT00637039). Results: 20 pts with advanced refractory tumors (16 breast) received AZD8931. Median exposure to AZD8931 was 52 days and to P was 3 cycles. In the 160 mg bid cohort, DLTs occurred in 2/6 pts (Gr 3 rash; Gr 3 keratitis and Gr 3 photophobia), leading to lower dose cohorts. DLTs occurred in 1/2 pts at 120 mg bid (Gr 3 diarrhea) and 2/6 pts at 80 mg bid (Gr 3 rash; Gr 3 esophagitis). AZD8931 40 mg bid was the protocol-defined MTD. At AZD8931 40 mg bid + P, skin rash (n=6) and diarrhea (n=5) were the most common dermatology and GI-related AEs; the majority were of short duration, and responded to appropriate management and/or temporary AZD8931 interruption. At 40 mg bid, AZD8931 steady-state concentrations exceeded preclinical IC50s for target receptors. Combination treatment did not alter exposure of AZD8931 or P (preliminary data). Conclusions: AZD8931 40 mg bid was generally well tolerated, considered suitable for chronic administration, and is progressing into phase II. Experience in this study has highlighted the importance of early rash management and robust guidelines have been adopted. The difference in AZD8931 MTD between this and the monotherapy study most probably reflects differences in clinical interpretation of DLT criteria as they pertained to non life-threatening and subjective events such as rash, more long-term exposure in the present study, and the possible augmentation of rash when EGFR inhibition is combined with P.